|
|
| ÂÒÇÒÃì¿ÒÃÔ¹ | 7 |  | 2.69 |
| ÂÒÅÐÅÒÂÅÔèÁàÅ×Í´ | 6 | | 2.31 |
| pseudoephedrine ¤×Í | 5 | | 1.92 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 84 (¾.È.2527) | 4 | | 1.54 |
| methylphenidate | 4 | | 1.54 |
| ÂÒʵÃÕà¾çÀÒ¤ ÊÃþ¤Ø³ | 4 | | 1.54 |
| Êӹѡ§Ò¹ÍÒËÒÃáÅÐÂÒ à¤Ã×èͧÊíÒÍÒ§¤ì | 3 | | 1.15 |
| «Ù¤ÃÒâÅÊ ¤×Í | 3 | | 1.15 |
| ÈÙ¹ÂìÇԷºÃÔ¡Òà | 3 | | 1.15 |
| path ã¹ tomcat äÁè start º¹ window | 2 | | 0.77 |
| ÁÍ¡. 14-2525 | 2 | | 0.77 |
| ÈØÀ¡Ô¨ Ãѵ¹ÈÔÃÔÁ¹µÃÕ | 2 | | 0.77 |
| ÍÒËÒùÓà¢éÒà¾×èÍÊè§ÍÍ¡ ¢Í Í | 2 | | 0.77 |
| sowt à¤Ã×èͧÊÓÍÒ§ | 2 | | 0.77 |
| ¡®ËÁÒÂÍÒËÒÃáÅÐÂÒ | 2 | | 0.77 |
| «Ùâ´ÍÕà¿´ÃÕ¹ ¤×ÍÂÒÍÐäà | 2 | | 0.77 |
| powerpoint ¤ÇÒÁÃÙé¾×é¹°Ò¹à¡ÕèÂǡѺâä áÅСÒÃãªéÂÒ | 2 | | 0.77 |
| àÅ¢·ÐàºÕ¹ÂÒ g 244/43 | 2 | | 0.77 |
| ¡ÒÃÅéÒ§¼Ñ¡ ¼ÅäÁé ÍÂ. | 2 | | 0.77 |
| ËéͧÊÁØ´ Í | 2 | | 0.77 |
| àËç´ËÔé§à·Ò¤ÇѹºØËÃÕè | 2 | | 0.77 |
| ÂÒÊÅÒÂÅÔèÁàÅ×Í´ | 2 | | 0.77 |
| ¡ÒÃá¾éÂÒ¡ÅØèÁ quinolone | 2 | | 0.77 |
| ºÃÔÉÑ·¡Òá¿¿ÃÕ« àÍç¡«ìµÃéÒ | 2 | | 0.77 |
| ·Óà¹Â¶ÑèÇ¡Ô¹àͧ | 2 | | 0.77 |
| ÊØ¢ÀÒ¾¼ÙéºÃÔâÀ¤ | 2 | | 0.77 |
| ÊÁعä¾ÃâËÂè§àËÔ§ | 2 | | 0.77 |
| ¡®ËÁÒÂÍÂ. | 2 | | 0.77 |
| «Ùâ´ÍÕà¿´ÃÕ¹ ¤×Í ÍÐäà | 2 | | 0.77 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 34 | 2 | | 0.77 |
| ¢éÍÁÙÅ¡ÒùÓà¢éÒáÅÐÊè§ÍÍ¡+à¤Ã×ͧÊÓÍÒ§ | 2 | | 0.77 |
| sls ÁÐàÃç§ | 1 | | 0.38 |
| â¤Ã§¡ÒÃà¹×éÍÊѵÇì͹ÒÁÑ ¡ÃÁ»ÈØÊѵÇì¡ÃзÃǧà¡ÉµÃáÅÐÊˡóì | 1 | | 0.38 |
| ÂÒ¹éÓÊ¡Ñ´âÊÁà¡ÒËÅյѧ¡Ø¨Ѻ ÃéͧàÃÕ¹ | 1 | | 0.38 |
| ÂÒ¾ÒÃÒáÁèàÅ×è͹ ¢Ñº¹éÓ¤ÒÇ»ÅÒ | 1 | | 0.38 |
| ¡ÒÃãªéÂҪش | 1 | | 0.38 |
| äÊé¡ÃÍ¡bk | 1 | | 0.38 |
| â¤Ã§¡ÒþѲ¹Òà¤Ã×Í¢èÒ¤³Ð¡ÃÃÁ¡ÒäØéÁ¤Ãͧ¼ÙéºÃÔâÀ¤ | 1 | | 0.38 |
| ÂҪشÍѹµÃÒ | 1 | | 0.38 |
| ¡Í§¤Çº¤ØÁÇѵ¶ØàʾµÔ´. âäÍéǹáÅлÑËÒ¡ÒÃãªéÂÒÅ´¤ÇÒÁÍéǹ㹻ÃÐà·Èä·Â | 1 | | 0.38 |
| ¡ÒüÅÔµà¤Ã×ͧÁ×Íá¾·Âì ¢Í§Õè»Øè¹ | 1 | | 0.38 |
| ÍÒËÒÃáÅÐÂÒ | 1 | | 0.38 |
| àÁ×èÍ¡Ô¹ÂÒÊàµÕÂÃÍ·ÓãËéÍÒ¡ÒûǴàÁ×èÍÂËÒÂÍÂèÒ§ÃÇ´àÃçÇ | 1 | | 0.38 |
| »ÃÒªìÊ͹ÇèÒ+ÈØÀ¹ÔÁÔµ | 1 | | 0.38 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 40 ¾.È.2548 | 1 | | 0.38 |
| áÍÅàÍÊ´Õ (lsd lysergic acid diethylamide) | 1 | | 0.38 |
| ¡Å×¹¶èÒ¹¡ÃдØÁ | 1 | | 0.38 |
| º à¨ÃÔâÍʶ | 1 | | 0.38 |
| ªÓÃФèÒ¸ÃÃÁà¹ÕÂÁÃÒ»Õà¤Ã×èͧÊÓÍÒ§ | 1 | | 0.38 |
| cancer screening guidelines | 1 | | 0.38 |
| ¡ÃÁ͹ÒÁÑÂÍÒËÒÃáÅÐÂÒ ¼ÅÊͺ | 1 | | 0.38 |
| §Ò¹»ÃÒºÊÒÃàÃè§à¹×éÍá´§ | 1 | | 0.38 |
| ¡®ËÁÒ©ÅÒ¡à¤Ã×èͧÊÓÍÒ§ | 1 | | 0.38 |
| multidrug tb resistance tb ppt | 1 | | 0.38 |
| âäÇÑǺéÒ ÁÕ㺠cer | 1 | | 0.38 |
| ˹éÒ´èÒ§¢ÒÇ | 1 | | 0.38 |
| ÍÕ¿Ô´ÃÕ¹ | 1 | | 0.38 |
| à¤Ã×èͧÊíÒÍÒ§·Õè ÍÂ.ËéÒÁãªé | 1 | | 0.38 |
| «Ù¤ÃÒâÃÊ ÍѹµÃÒ | 1 | | 0.38 |
| á»Å¼Å framingham heart score | 1 | | 0.38 |
| ÂÒµÃÕ¹ÔÊÔ§àË ËÁÍÁÕ | 1 | | 0.38 |
| ºÃÔÉѵԤÃÕÁ exxe | 1 | | 0.38 |
| alcohol+¡Åä¡ÂÒ | 1 | | 0.38 |
| ÍѹµÃÒ ¨Ò¡ ÂÒ ªØ´ | 1 | | 0.38 |
| ¹éÓµÒÅ«Ù¤ÒâÃÊ+·ÕèÁÒ | 1 | | 0.38 |
| "Á³±Ò·Ô¾Âì ªÔ¹ÇѵÃ" + "ÊÔ¹º¹" | 1 | | 0.38 |
| à¤Ã×èͧÊÓÍÒ§·ÕèÁÕ¢ÁÔ鹪ѹ¢Í§Í§¤ì¡ÃàÀÊѪ¡ÃÃÁ | 1 | | 0.38 |
| paracetamol ÊÃþ¤Ø³ | 1 | | 0.38 |
| ¢ÒÂÂÒá¡éä͹éÓ´Ó äÁèà¡Ô¹ Í | 1 | | 0.38 |
| °Ò¹¢éÍÁÙÅ¡ÃзèÍÁ | 1 | | 0.38 |
| »ÃСÒȤ³Ð¡ÃÃÁ¡ÒäǺ¤ØÁÂÒàʾµÔ´ãËéâ·É | 1 | | 0.38 |
| à¡ÕèÂǡѺÂÒ ¤ÅçÍ¡«Ò«ÔÅÅÔ¹ ËÃ×Í ÍÕÃÔâ·ÃäÁ«Ô¹ | 1 | | 0.38 |
| ÂÒá¡éËÇÑ´ ¹éíÒÁÙ¡äËÅ | 1 | | 0.38 |
| ÂÒzytiga | 1 | | 0.38 |
| ÁËÒÇÔ·ÂÒÅÑÂà¡ÉµÃͺÃÁ¡ÒáӨѴ»ÅÇ¡ | 1 | | 0.38 |
| à¤ÁպӺѴ âç¾ÂÒºÒÅÁËÒÃÒª | 1 | | 0.38 |
| ÇԨѼÙéºÃÔâÀ¤ºÐËÁÕè¡Öè§ÊÓàÃç¨ÃÙ» | 1 | | 0.38 |
| ¤ÃÕÁá͹¹Ò ¤ÍÊàÁµÔ¡Êì | 1 | | 0.38 |
| ¢éÍ¡Ó˹´¡¯ËÁÒ aspartame | 1 | | 0.38 |
| ¡¯ËÁÒ ÍÂ. | 1 | | 0.38 |
| ÂÒʵÃÕà¾çÀҤ᤻«ÙÅ | 1 | | 0.38 |
| ÇѤ«Õ¹ erig | 1 | | 0.38 |
| «Ùâ´ÍÕà¿´ÃÕ¹¤×ÍÍÐäà | 1 | | 0.38 |
| ª¹Ô´¢Í§ÂÒªÒ | 1 | | 0.38 |
| ¤ÃÕÁÁÔÊÅÔÅÅÕè | 1 | | 0.38 |
| ¢éʹբͧ«Ù¤ÒâÃÊ | 1 | | 0.38 |
| Êӹѡ§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 1 | | 0.38 |
| ¢ÒÂÊÕ¼ÊÁÍÒËÒà ¸ÃÃÁªÒµÔ | 1 | | 0.38 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè 295 | 1 | | 0.38 |
| ¡ÒÃ¢Í certificate of origin ÊÓËÃѺ¢Í fda | 1 | | 0.38 |
| «×éÍÂҹ͹ËÅѺ¼Ô´ËÃ×ÍäÁè | 1 | | 0.38 |
| »ÃСÒÈ«Ùâ´ÍÕà¿´ÃÕ¹ | 1 | | 0.38 |
| ¡ÒÃÊ׺¤é¹áººbrowse | 1 | | 0.38 |
| ÍÂ. | 1 | | 0.38 |
| ÂÒÊÅÒÂÅÔéÁàÅ×Í´ | 1 | | 0.38 |
| ¢èÒÇ¢¹ÁµÔ´¤Íà´ç¡ | 1 | | 0.38 |
| «ÍÊ»ÃاÃʤ×ÍÍÐäà | 1 | | 0.38 |
| ÂÒ»éͧ¡Ñ¹àÅ×Í´á¢ç§µÑÇ | 1 | | 0.38 |
| ¢ÒÂÂÒá¼¹»Ñ¨¨ØºÑ¹â´ÂäÁèä´éÃѺ͹ØÒµ | 1 | | 0.38 |
| ¡ÒõÃǨ«ÑÅ俵ì㹡Øé§ | 1 | | 0.38 |
,
User's Guide
˹éÒÅçÍ¡ÍÔ¹| ʶԵÔÃÒ»Õ
| ʶԵÔÃÒÂà´×͹
| ʶԵÔÃÒÂÇѹ
| ʶԵÔÃÒªÑèÇâÁ§
| Eng
Pageview 
Unique IPs 
Sessions